01255nas a2200205 4500000000100000008004100001653003000042653001700072653001300089653001200102100001300114700001200127700001100139700001400150245006900164856008700233490000700320520070900327022001301036 2016 d10aZero leprosy transmission10aTransmission10aStrategy10aleprosy1 aSmith WC1 aAerts A1 aKita E1 aVirmond M00aTime to define leprosy elimination as zero leprosy transmission? uhttp://www.thelancet.com/journals/laninf/article/PIIS1473-3099(16)00087-6/fulltext0 v163 a

In 1982, in response to growing evidence of resistance to the antibacterial drug, dapsone, WHO recommended that all patients with leprosy be treated with a short-course combination of three antibacterial drugs, rifampicin, dapsone, and clofazimine.1 This multidrug therapy reduced the number of patients with leprosy being treated from 5·3 million in 1985 to 3·1 million in 1991.2 The reduction in prevalence inspired the World Health Assembly in 1991 to set a target to eliminate leprosy as a public health problem by 2000, defining elimination as a global prevalence rate below one case per 10 000 of the population.

 

 

 

 a14733099